Eye disease Clinical Trials

82 recruitingLast updated: May 13, 2026

There are 82 actively recruiting eye disease clinical trials across 40 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Bethesda, Maryland, United States, Memphis, Tennessee, United States, Newport Beach, California, United States. Updated daily from ClinicalTrials.gov.


Eye disease Trials at a Glance

82 actively recruiting trials for eye disease are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Not Applicable with 20 trials, with the heaviest enrollment activity in Bethesda, Memphis, and Newport Beach. Lead sponsors running eye disease studies include National Eye Institute (NEI), Laboratoires Thea, and Duke University.

Browse eye disease trials by phase

Treatments under study

About Eye disease Clinical Trials

Looking for clinical trials for Eye disease? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Eye disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Eye disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 82 trials

Recruiting

Genetics of Inherited Eye Disease

genetic eye disease
National Eye Institute (NEI)1,500 enrolled1 locationNCT02471287
Recruiting

Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

genetic eye disease
National Eye Institute (NEI)2,000 enrolled1 locationNCT02077894
Recruiting
Not Applicable

Upper Punctal Plug Occlusion in Previous Lower Punctal Occlusion.

DEDAqueous-deficient Dry Eye Disease
Universidad Autonoma de Nuevo Leon36 enrolled1 locationNCT07571330
Recruiting
Phase 2Phase 3

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Dry Eye Disease (DED)
Oculis160 enrolled10 locationsNCT07548632
Recruiting

Screening for Research Participants

Eye Diseases
National Eye Institute (NEI)10,000 enrolled1 locationNCT00655096
Recruiting
Phase 4

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

Dry Eye Disease (DED)
Southern California College of Optometry at Marshall B. Ketchum University30 enrolled1 locationNCT06655441
Recruiting
Not Applicable

The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes

Dry Eye Disease (DED)
The University of New South Wales60 enrolled1 locationNCT06898853
Recruiting
Phase 2

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Graves OrbitopathyGraves OphthalmopathyThyroid Eye Disease (TED)
The First Affiliated Hospital of Xiamen University8 enrolled1 locationNCT07547930
Recruiting

Clinical and Molecular Studies in Families With Inherited Eye Disease

Inherited Eye Disease
National Eye Institute (NEI)5,000 enrolled10 locationsNCT02771236
Recruiting
Not Applicable

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

Graves OphthalmopathyThyroid Eye Disease (TED)
Taipei Veterans General Hospital, Taiwan120 enrolled1 locationNCT07400757
Recruiting

Natural History, Pathogenesis, and Outcome of Ocular Disorders

Eye disease
National Eye Institute (NEI)1,000 enrolled1 locationNCT02821767
Recruiting
Not Applicable

The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

GlaucomaEye DiseasesCornea Disease
Centre hospitalier de l'Université de Montréal (CHUM)20 enrolled1 locationNCT04232982
Recruiting

Natural History Study of Patients With EYS-Associated RP

Retinitis PigmentosaEye Diseases
Sensor Technology for Deafblind45 enrolled1 locationNCT07228793
Recruiting
Not Applicable

RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)

TrachomaEye DiseasesTrichiasis
University of North Carolina, Chapel Hill1,000 enrolled2 locationsNCT07322302
Recruiting
Phase 1Phase 2

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Thyroid Eye Disease
Amgen88 enrolled30 locationsNCT06401044
Recruiting
Phase 3

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

Thyroid Eye Disease (TED)
Minghui Pharmaceutical (Hangzhou) Ltd258 enrolled1 locationNCT07262476
Recruiting
Phase 3

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Thyroid Eye Disease (TED)
Minghui Pharmaceutical (Hangzhou) Ltd150 enrolled1 locationNCT07257185
Recruiting
Phase 4

SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease

Dry Eye Disease (DED)
Indiana University260 enrolled4 locationsNCT07243275
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

AsthmaVasculitisInflammatory Disease+2 more
Imperial College London120 enrolled1 locationNCT05012033